Skip to content
OpenCapital
Get started

Allogene Therapeutics ALLO Q4 2025 Annual earnings

Reported March 12, 2026 · After market close

Revenue-Miss by $2.5KDiluted EPS-$0.17Beat by $0.08
Revenue estimate$2.5K
EPS estimate-$0.25

Next report

Aug 12, 2026 (in a month)
Revenue estimate$2.2K
EPS estimate-$0.16

Financials

Q4 2025

Income statement

See full
Revenue-—
Operating income-$42.4M+29.9%
Net income-$38.8M+35.3%
EPS (diluted)-$0.17+39.3%

Balance sheet

See full
Cash & equivalents$62.0M-27.5%
Total debt$83.3M-8.3%
Total equity$292.5M-30.7%
Total assets$415.9M-24.2%

Cash flow

See full
Operating cash flow-$27.6M+24.8%
CapEx--100%
Free cash flow-$27.6M+25.3%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$307.88M-31.1%
Enterprise value$329.15M-27.2%

Returns & leverage

See full
Return on equity-53.4%-1.6pp
Debt / equity0.3×+0.1×
Current ratio7.9×-0.6×

Versus estimates

Revenue

Q4 2024$22.0KBeat by $10.0K

Diluted EPS

Q1 2026-$0.18Beat by $0.01
Q4 2025-$0.17Beat by $0.08
Q3 2025-$0.19Beat by $0.04Q2 2025-$0.23Beat by $0.05Q1 2025-$0.28In lineQ4 2024-$0.28Beat by $0.06

Ask the moment Allogene Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Allogene Therapeutics report Q4 2025 earnings?
Allogene Therapeutics (ALLO) reported Q4 2025 earnings on March 12, 2026 after market close.
What were Allogene Therapeutics's Q4 2025 revenue and EPS?
Allogene Therapeutics reported revenue of - and diluted EPS of $-0.17 for Q4 2025.
Did Allogene Therapeutics beat estimates in Q4 2025?
Revenue missed the consensus estimate of $2.5K by $2.5K. EPS beat the consensus estimate of $-0.25 by $0.08.
How did Allogene Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $22.0K a year earlier and diluted EPS grew 39.3% from $-0.28.
Where can I find Allogene Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001628280-26-017230) and the 10-K periodic report (0001628280-26-017242) directly on SEC EDGAR. The filing index links above go to sec.gov.